Added SNSS - on a forward looking event..Good entry

Lifeline Biotechnologies Expects FDA Consulting Firm's Report

businesswire
Press Release Source: Lifeline Biotechnologies, Inc. On Monday May 3, 2010, 1:20 pm

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO - News) today reported expectations of its FDA consultant’s report by the middle of this month. The anticipation is based on the commitment by Lifeline’s FDA consulting firm.

Jim Holmes, Lifeline's CEO, said, “This past January we retained an FDA consulting firm to review our clinical processes and our software systems in order to ensure compliance with FDA verification and validation requirements. We have been working closely with these consultants, providing the information they have requested. The firm has concluded its study for Lifeline’s regulatory strategy and is preparing their findings in a report to be delivered shortly. This firm was retained to the review the existing product, the clinical trial records, as well as the intended use and marketing claims of our First Warning System™. The overall task of the consulting firm is to define a regulatory strategy for the First Warning System™ to obtain product commercialization.”

Doctor Louis Keith, Lifeline’s Vice President and Medical Director, said, “We are eager to receive the consultant’s report. From this study our expectation is to prepare and submit an application to the FDA for a 510(k) marketing clearance.”

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Jim Holmes, 775-324-1933
Jholmes@lbti.com
www.lbti.com

ADVENTRX Announces 6-Month Stability Data Results for ANX-530
prnewswire

Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Monday May 3, 2010, 8:30 am

SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.

"These results are what we expected and what we expect to see from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once we have the 12-month data, we will submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that future stability testing results are not consistent with prior results or are out-of-specification or otherwise do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; the risk that the FDA does not accept a submitted Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; ADVENTRX's dependence on the success of Exelbine, and uncertainty as to whether Exelbine will receive regulatory approval or be commercialized successfully; the risk that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine®; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial, and that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; the potential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which its operating funds will sustain it; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development
globenewswire

Press Release Source: Hemispherx Biopharma, Inc. On Monday May 3, 2010, 8:00 am

PHILADELPHIA, May 3, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE AMEX:HEB) (the "Company") announced today the formation of an Independent Data Monitoring Committee (DMC) which will oversee the Company's various drug development programs. The principal role of an independent DMC is to perform interim analyses of the clinical outcome data and to insure the safety of patients in clinical trials. The DMC also plays a critical role in studies that may use Adaptive Design wherein trial design modifications can be made after patient enrollment has started. Adaptive Design will enable Hemispherx to respond to data collected during the trial which may include dropping a treatment arm, modifying the sample size, etc, to increase statistical probability of reaching the desired therapeutic outcome.

The three members of the DMC are Thomas R. Zimmerman Jr., MD, F.A.A.N., Philip R. Roane, Jr., Ph.D. and Anita F. Das, Ph.D. Dr. Zimmerman will act as chairman. They will be the core members of the DMC and, from time to time, their skills and knowledge may be supplemented by experts who bring knowledge of a given indication, geographic familiarity, etc. to the Committee for particular studies.

Dr. Zimmerman has over 12 years of medical monitoring experience for all phases of clinical trials, including safety reporting and narrative writing for NDA's and is a Clinical Associate Professor of Neurology at Robert Wood Johnson Medical School. Dr. Roane is an Associate Professor and Vice Chairman of the Department of Microbiology at Howard University and has served on numerous scientific review panels for the National Institutes of Health and the Department of Defense. Dr. Das is President and Principal Biostatistician of AxiStat, Inc. She serves on the Data and Safety Monitoring Committee established by the Best Pharmaceuticals for Children Act which seeks to improve pediatric therapeutics.

By having a formal independent DMC, the Company puts in place a cumulative and broad knowledge gained by DMC members over the course of multiple clinical studies in multiple treatment indications thus further accruing to the benefit and safety of patients suffering from serious diseases without adequate present therapies. The Company has in the planning stages a number of studies for Ampligen(R) , an investigational therapeutic, and Alferon N Injection(R), both in the U.S. and abroad, including the recently announced initiative in India with Alferon N Injection(R) for the treatment of seriously ill patients hospitalized with influenza, scheduled to begin in the upcoming monsoon season.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx' flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) and Alferon LDO. Ampligen(R) represents experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx' platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R) and Alferon(R) LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications. Further, the commencement of clinical trials in June, 2010 by Max Neeman in India is its target date but cannot be guaranteed due to a variety of risk factors outside of the parties control and should be regarded only as a forward looking estimate.

Contact:

Hemispherx Biopharma, Inc.
Dianne Will
518-398-6222
ir@hemispherx.net

Interesting Article for POSC followers.. The U.S. Market for SPECT and PET Radiopharmaceuticals

The Radiopharmaceutical Report Includes:

* Analysis of Current and Future Radiopharmaceutical Markets
* Emerging Markets For New Molecular Imaging Platforms
* Good Growth Prospects for New SPECT and PET Radiopharmaceuticals
* Long-Term Effects of the Technetium Shortage on the SPECT Market
* Good Prospects for New PET Cardiology Products and Rubidium PET
* Big Markets for New PET and SPECT Agents for Alzheimer's and Parkinson's
* Promising New PET Oncology Products with Broad Applications
* Technological Trends and Competitive Challenges
* Market Assessment and Sales Forecasts to 2017

The report has a strong focus on new products and technology and emerging market opportunities. This covers nuclear cardiology with both PET and SPECT, targeted oncology and new molecular imaging platforms for PET. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease with PET and SPECT. This will broaden the base of nuclear medicine and allow nuclear imaging to compete more effectively in the larger imaging marketplace.

There has been some decline in the number of SPECT myocardial perfusion procedures as well as reduced pricing for Cardiolite and Myoview because of generic sestamibi. The technetium shortage has also added pressure that will continue for the near term. This will encourage more physicians to adopt PET for many cardiology applications as soon as the new perfusion agents are approved. Cardiology PET produces better images and offers higher reimbursement than traditional cardiology SPECT. This is also stimulating the market for rubidium PET. Growth is still expected in cardiology SPECT from specialized products for imaging myocardial infarction and neuronal imbalances in patients that need pacemakers or may be subject to congestive heart failure. These products are in late stage development and will be introduced in the near term.

New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting. This includes new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. This will aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. In the long run, this will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth.

SPECT and PET Radiopharmaceuticals: Market Analysis and Future Prospects
U.S. sales of SPECT and PET radiopharmaceuticals reached $1.16 billion in 2009 and are expected to rise to $4.76 billion by 2017. Total SPECT radiopharmaceutical sales were down 11.6% in 2009 primarily due to reductions in pricing of perfusion agents with the introduction of generic sestamibi. SPECT procedure volume was also down due to the technetium shortage. These pressures will continue in 2010, but eventually stabilize. In comparison, PET procedures were flat compared with the previous year, but revenue was down slightly because of price weakness in the FDG market. However, future sales growth will be more in line with procedure growth.

Although PET reimbursement has been under pressure for the past 2 years, there has been some relief recently. New indications have been approved and reimbursement has improved for certain procedures, particularly in cardiology. Investment in new PET agents is increasing in all segments, which bodes well for this market once the new products are introduced.

Continuing improvements in imaging technology in both SPECT and PET are allowing higher resolution and shorter imaging times. Radiopharmaceutical doses are also going down due to increased imaging efficiency. This makes nuclear medicine safer than many other imaging modalities, which are threatened with excessive radiation and patient safety issues.

As new products are introduced, SPECT sales should more than double during the forecast period from $817 million in 2009 to $1,737 million by 2017. PET sales will increase more rapidly from $348 million in 2009 to $3,028 million by 2017, an increase of more than 700%. This will come primarily from new products as well as increases in the volume of FDG procedures. Market growth will also result from higher prices of the new products. This influx will help all segments of nuclear medicine expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.

I am adding more CYTX on Monday.Will move higher on forward looking news.Thanks,barefootrunner,as always great DD!I look forward to Friday.

Thank you Kei ! you are an asset to our board.

POZEN Announces May 3, 2010 Webcast

Link http://biz.yahoo.com/cc/5/113585.html

POZEN Inc. (NASDAQ: POZN), announced today that management will hold a live webcast on May 3, 2010 at 8:30 a.m. Eastern time to discuss regulatory updates regarding VIMOVO™ (naproxen and esomeprazole magnesium) delayed-release tablets. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay.

About POZEN

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company’s common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

Monday AM

CCCP great call on POZN!! You called it early on and hit ,once again, a home run.You are a BIO-GURU! Thank you....another FDA PLAYS success!

CCCP great call on POZN!! You called it early on and hit ,once again, a home run.You are a BIO-GURU! Thank you....another FDA PLAYS success!

Barefootrunner....Your exactly right,Classic

I don't think you would get executed until it reopens again which could be at a much lower price.

Ask your broker,mine is E-trade to hide your stop. This way the MMs cannot see it.

My opinion is definitely put in a trailing stop for lets say 10%.If POZN does not get approved,it will protect you,as it will turn into a market order which gets priority in executing.Plus it trails even if the stock goods up which is also a great feature.

BMR News: Positron's CEO Believes Impact of New Technology and Partnerships Will Make Company Significantly More Profitable Than Ever

http://biomedreports.com/articles/most-popular/38340-positron-ceo-believes-impact-of-new-technology-and-partnerships-will-make-company-significantly-more-profitable-than-ever.html

Written by M.E.Garza
Friday, 30 April 2010 03:19

Patrick G. Rooney, the Chairman of the Board of Positron Corporation (OTC:POSC.OB) - a molecular imaging company focused on Nuclear Cardiology- has confirmed in an exclusive interview with BioMedReports that while his company will be profitable this year, he sees it becoming much more profitable next year and so on- year over year- going forward.

While his candid comments to us appeared bold and optimistic, his estimates apparently did not include some of the resources and capabilities that will be brought to the table for POSC by some of the partnerships that are about to be announced publicly.

"Once you add those relationships, the revenue and profit numbers increase significantly," explains Rooney. "It’s very significant.”

BioMedReports learned yesterday that while POSC's position as the leading Cardio PET imaging manufacturer makes the company very attractive to small and micro-cap investors, it's revolutionary Pharm-Assist® automated radiopharmaceutical distribution device is what has attracted the attention of not only one multi-billion dollar NYSE company which has already inked a yet-to-be announced deal with Positron, but other publicly traded, large cap companies as well.

Rooney spoke exclusively to us about the technologies and strategic alliances his company will be presenting at POSC's upcoming news conference at the Nasdaq MarketSite in New York City.

The following is a transcript of Rooney's comments to us:

"In 2008, we acquired a company in Indianapolis and this company brought us two things, they brought us pharmaceutical expertise and they brought us a device that looked like a large, fat refrigerator. What this device does is pretty incredible. It’s an automated virtual pharmacy.

"The way the world works now, if you want to get your heart imaged, your doctor picks up the phone and calls a registered pharmacy specializing in the preparation and delivery of radioactive drugs (radiopharmacy). Once they get the right person on the phone, they order a dose or a ‘syringe’ – a cocktail of the right radiopharmaceutical. You get injected with it and then you get imaged.

"There are about five hundred of these special pharmacies across the country, many of which are run by Cardinal Health, Covidien and General Electric Co. What our device does, is that it compounds these same radiopharmaceuticals on site. So literarily, we can install these devices at hospitals or at the cardiologist’s office so that when I walk in as a patient, they’re not saying ‘hey come back tomorrow so that we have time to order you a dose of radioactivity.’ Instead, the doctor hits some buttons and the dose comes out of this ‘vending machine,’ if you will.

"Our (Pharm-Assist®) machine is not only a very attractive option for patients and doctors, but also to many of the current companies and drug manufacturers who deal in the cardiac and oncology imaging space because instead of taking on the expense of opening up a brick and mortar location for $3+ million and being worried about the expensive overhead and personnel costs of selling radiopharmaceuticals, we can install this inexpensive, automated device that is compliant with all the U.S. rules and regulations for safety and exposure issues. It works well in emergency rooms, in cardiology offices, etc. There are many benefits to it, including the fact that it saves a great deal of money, gas, and time. In addition, if you’re trying to get a dose and you’re the 10th person in line ordering, you may not get the dose. With our system, you’re guaranteed to get a dose.

"With this component, POSC brings in the imaging, the dose dispensing of these radiopharmaceuticals to the doctor’s office. So what’s going to happen in the coming months is we’re going to be offering full solutions to the industry. We’re going to say, ‘Hey doc, we can get you a PET camera and we can get it to you as a rental, thanks to our new finance partners, or as an outright sale/purchase. In addition, in a very similar way to which someone puts in a vending machine, we’ll install our automated pharmacy device and sell the drug products through it at a better price while being more efficient and more effective.

"The current technologies, including all the old SPECT imaging systems that are out there, are all outdated. They’re also more expensive and invasive. For example, 35% of the time, the use of a SPECT imaging system requires that additional imaging work be done in order to get a clearer picture of what is going on. Our PET scan technology works and it’s the future of medicine. Government healthcare agencies, insurance companies, and everyone else involved prefers it, that’s why it’s important that we’re the undisputed leader in the cardiac PET field. When you give a patient a PET scan, across the board the results are much clearer and the technology works. It will tell you in a clear and unambiguous fashion what your issue is. A patient doesn’t need to have someone go into their artery in order to put something into their heart to have a look at what is going on.

"These technologies have brought us a wave of new interest for partnerships, strategic alliances and, frankly, we’re having to start staffing and hiring much faster than ever before. We’re a company that has been waiting for the evolution to come and now we find that it’s coming on stronger than we thought.

"Although it has taken some time, development and really honing in all of our components, we are there now.

"We will be profitable this year, much more profitable next year and so on- year over year going forward; and that doesn’t include some of the resources and capabilities that will be brought to the table by some of the partnerships that are about to be announced. Once you add those relationships, the revenue and profit numbers increase significantly. It’s very significant.”

Company shares gained 48% after Rooney's comments to BioMedReports two days ago, before giving up $.02 in Thursday's trading action. Analysts expect that shares will continue to trend higher as we get closer to Wednesday's press conference in New York City.



Disclosure: Long POSC




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

Inergetics Enters Three-Year Agreement With Windmill Health Products to Sell and Market Its Surgex(TM) Sports Supplement Line Worldwide
Inergetics' CEO Projects Sports Nutritional Line to Capture 1% to 2% of the Nutritional Supplement Market by 2012
globenewswire

Press Release Source: Inergetics, Inc. On Friday April 30, 2010, 8:00 am

PARAMUS, N.J., April 30, 2010 (GLOBE NEWSWIRE) -- Inergetics, Inc. (OTCBB:MBTG - News), a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has agreed in principle with Windmill Health Products to a three year exclusive distributor relationship to sell and market its Surgex(TM) sports supplement across multiple classes of trade worldwide.

Surgex(TM) is a clinically validated nutritional supplement formulated to improve athletic performance through optimized recovery. Surgex contains an enhanced proprietary blend of nutrients scientifically designed to increase peak power, improve endurance, accelerate recovery, and build lean muscle mass by significantly decreasing oxidative stress, inflammatory markers and cortisol. It has been used in the NBA and other professional sports, is NCAA compliant, and has passed the rigorous testing criteria established by the Banned Substance Control Group (BSCG), having been found to contain no banned substances.

Mark Mirken, CEO of Inergetics, Inc., commented, "There is no other sports nutritional product on the market today that contains Surgex's patent-protected nutritional composition combined with the product's published trials. With this distribution agreement in place, along with other developing opportunities, we project that our sports product line will penetrate 1% to 2% of the worldwide nutritional supplement markets by 2012."

Windmill Health Products LLC is a leading marketer and distributor of Lifestyle nutritional products worldwide. Windmill distributes and markets products to all major classes of trade, which includes Food, Drug, Mass Market and Health Food retailers and distributors.

Rich Lauritano, VP of Special Markets for Windmill Health Products, stated, "We have a timely and unique opportunity with Surgex and look forward to introducing this clinically validated brand here in the US and to the international markets.

"Inergetics' current Surgex(TM) line allows athletes at all levels to train harder and therefore compete better; and their proprietary science will set them apart from all other products in their category. As they expand their brand with other products which are now in development and through Windmill Health Products LLC, the value of the Company's sales and brand will grow exponentially."

Garden State Nutritionals (GSN), a division of Vitaquest International, a global leader in the manufacturing of lifestyle specific nutritional supplements, will be the manufacturer of Surgex's nutritional formulas in its powdered form.

Keith Frankel, President & CEO of Vitaquest International, commented, "We have partnered with Inergetics as it has expended time, effort and significant resources in the development of Surgex. Surgex(TM) is a unique, proprietary, patented and independently credentialed formula with statistically significant results as published in the 'Journal of Strength and Conditioning Research' and the 'Journal of Applied Exercise Physiology,' Surgex will completely 'change the playing field' for sports nutritional supplements in both its powdered and ready to drink format."

Mr. Mirken added, "This marks the critical first step in our strategic distribution plan which outlines the initial sale of Surgex throughout thousands of retail outlets, including convenience stores and large box store chains, first in powdered form, followed by a ready-to-drink version. Windmill has demonstrated the ability to sell products across diverse classes of trade both domestically and internationally and this agreement will tremendously increase and accelerate Surgex's market penetration."

To learn more about Surgex(TM), please visit www.surgexsports.com.

About Inergetics, Inc.

Inergetics, Inc. is a leading developer of nutritional supplements for the Clinical Health and Sports Supplement markets. The Company has established a line of Resurgex products consisting of proprietary nutritional formulas that are used by a wide range of clinical patients and consumers. Resurgex(TM) products provide comprehensive nutritional support for actively treated cancer patients as well as those in post-treatment care and elderly members of the assisted living community. Inergetics has also developed Surgex(TM) sports nutrition formula to meet the nutritional needs of professional, Olympic, and amateur elite athletes that experience post-workout symptoms such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and exceed the nutritional requirements of the assisted living community.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company and SPI set forth herein and those preceded by or that include the words "believes,'' "expects," "given," "targets,'' "intends,'' "anticipates," "plans,'' "projects,'' "forecasts'' or similar expressions, are "forward-looking statements". Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.

Contact:

Seal Point Consulting, LLC
Investor Contact
267-364-5407
Investors@sealpointconsulting.com

I agree. If he is wrong,watch subscriptions nose dive.I am still trying to figure this out. But,based on my own DD we still look good moving into the next Wednesday meeting.

Don't shoot the messenger LOL

Update Biomeds Alert-POSC....Pressed Released Special Report Coming on Friday.
After telling investors, "We believe Positron's (OTCBB:POSC) dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world." BiomedReports will feature a fully press-released special report and interview on the subject with Positron's CEO, Patrick Rooney this Friday.

BiomedReports today has learned that not only one, but multiple big board companies may have apparently taken great interest in POSC's Nuclear Pharm-Assist® technology and that some may have already inked deals involving the platform with the company.

While everyone has been focused on POSC's bright future as the leader and single buggest provider of Cardiac PET technology products, this morning Positron's CEO Patrick G. Rooney surprised investors by telling them that the company's radiopharmaceuticals business may be getting more attention going forward as well. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."

Update Biomeds Alert-POSC....Pressed Released Special Report Coming on Friday.
After telling investors, "We believe Positron's (OTCBB:POSC) dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world." BiomedReports will feature a fully press-released special report and interview on the subject with Positron's CEO, Patrick Rooney this Friday.

BiomedReports today has learned that not only one, but multiple big board companies may have apparently taken great interest in POSC's Nuclear Pharm-Assist® technology and that some may have already inked deals involving the platform with the company.

While everyone has been focused on POSC's bright future as the leader and single buggest provider of Cardiac PET technology products, this morning Positron's CEO Patrick G. Rooney surprised investors by telling them that the company's radiopharmaceuticals business may be getting more attention going forward as well. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."

Alert...Pozen on fire broke $12.00 resistance now $12.12

12!!!!

Barefootrunner, Thank you for the link.I feel solid with my SPPI investment.

Not yet....

POZN looking extremely strong..on DNDN news and shorts covering

SPPI up 7.5% looking good!

Paradigm Medical to Meet With Prospective Research Partners
marketwire

Press Release Source: Paradigm Medical Industries, Inc. On Thursday April 29, 2010, 11:57 am

SALT LAKE CITY, UT--(Marketwire - 04/29/10) - Paradigm Medical Industries, Inc. (Pinksheets:PDMI - News) announced today that Stephen L. Davis, the Company's President and CEO, will be attending ARVO, an ophthalmic research and product development meeting to be held in Ft. Lauderdale, Florida from May 1-5, 2010. Paradigm will utilize this meeting to introduce its new Paramax, which remains under FDA review, and its FDA approved Blood Flow Analyzer™ as new and innovative diagnostic devices for early detection of glaucoma. Mr. Davis will also meet with representatives from other ophthalmic research organizations to discuss opportunities for Paradigm to participate in new product development partnerships.

About Paradigm Medical Industries, Inc.

Headquartered in Salt Lake City, Utah, Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes ophthalmic diagnostic instruments and related products for early detection of glaucoma and other eye disorders. The Company's primary objective is to capture a niche market within the glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States and internationally.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

For more information, please visit: www.paradigm-medical.com
Contact:


Contact:
Paradigm Medical Industries, Inc.
Stephen L. Davis
President and Chief Executive Officer
Phone: 801-977-8970
Fax: 801 977-8973
www.paradigm-medical.com

BIOMED Alert...POSC Covidien (NYSE:COV)may have inked a deal with the company for part of the radiopharmaceutcial business.

I called management yesterday and asked if they will be changing the on-line ordering to allow credit card payments.Will advise

Like Sheff said before this is a total lotto play.Your strictly looking for a run up and then getting out.

Neoprobe Announces First Quarter Results

Business Update and Conference Call Scheduled

businesswire

Press Release Source: Neoprobe Corporation On Wednesday April 28, 2010, 4:35 pm

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2010. First quarter 2010 revenues were $2.7 million, consistent with the record revenue reported for the first quarter of 2009. Gross profit for the first quarter of 2010 was $1.8 million, compared to $1.9 million for the first quarter of 2009. Operating expenses increased to $3.5 million for the first quarter of 2010 from $2.1 million for the first quarter of 2009. Neoprobe’s loss from operations for the first quarter of 2010 was $1.7 million compared to $203,000 for the first quarter of 2009.

For the first quarter of 2010, Neoprobe reported a net loss attributable to common stockholders of $2.5 million, or $0.03 per share, compared to net income attributable to common stockholders of $754,000, or $0.01 per share, for the first quarter of 2009. As discussed more fully below, the first quarter 2009 net income attributable to common stockholders was primarily due to mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet.

Brent Larson, Neoprobe’s Vice President, Finance and CFO, said, “Gamma detection device revenue for the first quarter of 2010 remained steady compared to the same period in 2009. Increased probe sales volumes offset declines in console sales and a minor decline in sales prices. Gross margins from our device sales declined slightly to 67% for the first quarter of 2010 compared to 69% for the same period in the prior year due to net changes in product mix and the impact of the decline in sales prices. Our gamma detection device line continues to show strong overall results and generate cash flow to cover our corporate overhead and contribute to our product development costs.”

David Bupp, Neoprobe’s President and CEO, said, “Our operating expenses increased for the first quarter of 2010 compared to last year as chemistry, manufacturing and control activities and other development expenses associated with preparing to submit a new drug application (NDA) for Lymphoseek® have accelerated. During the first quarter of 2010, we were pleased to announce the positive outcome of a meeting with FDA regarding a review of results from our Phase 3 clinical trial for Lymphoseek in subjects with breast cancer or melanoma. Related to the positive outcome of the regulatory meeting and the activities necessary to support the NDA, we have added headcount and geared up other activities to prepare for and to support the filing of the NDA. We believe the positive outcome of this FDA meeting and our other activities have positioned us well for the filing of the NDA later this summer. Our general and administrative costs for the first quarter also increased compared to the prior year primarily related to increased stock and compensation costs.”

During the first quarter of 2009, the Company was required to adopt certain authoritative guidance related to the accounting treatment for derivative liabilities. Under the applicable accounting rules for financial instruments, embedded features of the Company’s notes and preferred stock and the related warrants to purchase common stock were considered derivative liabilities because these instruments contained language that provided for the resetting of the instruments’ exercise/conversion prices in the event that the Company issues common stock at prices below the exercise/conversion prices of the respective instruments. Treatment of these instruments as derivative liabilities resulted in them being required to be reflected on the Company’s balance sheet at their fair values (i.e., marked to market) based on certain assumptions, including the trading price of the Company’s common stock. The adoption of these rules resulted in our recording $1.5 million in non-cash income for the first quarter of 2009 related to marking such derivative liabilities to market as required by the guidance. Excluding the $1.5 million mark-to-market adjustment, the Company would have generated a net loss attributable to common shareholders of $771,000 for the first quarter of 2009. Neoprobe’s management believes, however, that the inclusion of such mark-to-market adjustments in the Company’s financial results does not appropriately communicate the results of the Company’s operating performance and development activities to our investors. As a result, Neoprobe’s management believes the ability of investors to analyze Neoprobe’s business trends and to understand Neoprobe’s performance may be better served from reviewing certain operational measures such as revenues, development expenses and income (loss) from operations. During the third quarter of 2009, Neoprobe agreed with the holder of the instruments with derivative characteristics to eliminate the price reset features that had substantially caused the derivative treatment of the instruments, thereby permitting the Company to effectively extinguish the majority of its derivative liabilities. This action should minimize the subsequent impact on our financial results which might have otherwise resulted from fluctuations in the trading price of the Company’s common stock.

Neoprobe’s President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company’s results for the first quarter of 2010 during a conference call scheduled for 11:00 AM ET, Thursday, April 29, 2010. During the conference call, Messrs. Bupp and Larson will provide a business update and discuss the Company’s results for the first quarter of 2010. Neoprobe’s Vice President, Pharmaceutical Research and Clinical Development, Frederick Cope, Ph.D., will also be available to respond to questions regarding Lymphoseek’s development progress.

Conference Call Information
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
Date: April 29, 2010 Available until: May 6, 2010
Time: 11:00 AM ET Toll-free (U.S.) Dial in # : 877-660-6853
International Dial in # : 201-612-7415
Toll-free (U.S.) Dial in # : 877-407-8033 Replay pass codes (both
International Dial in # : 201-689-8033 required for playback):
Account # : 286
Conference ID # : 349832

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

NEOPROBE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2010 2009
(unaudited)
Assets:

Cash $ 5,956,271 $ 5,639,842
Other current assets 2,726,780 2,977,323
Non-current assets 581,503 400,594

Total assets $ 9,264,554 $ 9,017,759


Liabilities and stockholders' deficit:

Current liabilities, including current portion of notes payable $ 3,422,520 $ 2,402,647
Notes payable, long term (net of discounts) 10,951,924 10,945,907
Derivative liabilities 2,380,956 1,951,664
Other liabilities 549,300 587,393
Preferred stock 3,000,000 3,000,000
Stockholders' deficit (11,040,146 ) (9,869,852 )

Total liabilities and stockholders' deficit

$

9,264,554

$

9,017,759



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
March 31, March 31,
2010 2009
(unaudited) (unaudited)

Total revenues $ 2,682,872 $ 2,682,221
Cost of goods sold 888,867 826,363
Gross profit 1,794,005 1,855,858

Operating expenses:
Research and development 2,401,672 1,221,969
Selling, general and administrative 1,128,202 837,323
Total operating expenses 3,529,874 2,059,292

Loss from operations (1,735,869 ) (203,434 )

Interest expense (284,438 ) (457,134 )
Change in derivative liabilities (429,292 ) 1,525,365
Other income, net 1,358 9,673

(Loss) income from continuing operations (2,448,241 ) 874,470

Discontinued operations (11,873 ) (60,349 )

Net (loss) income (2,460,114 ) 814,121

Preferred stock dividends (60,000 ) (60,000 )

Loss (income) attributable to common stockholders $ (2,520,114 ) $ 754,121

Loss (income) per common share (basic and diluted):
Continuing operations $ (0.03 ) $ 0.01
Discontinued operations $ (0.00 ) $ -
Loss (income) attributable to common stockholders $ (0.03 ) $ 0.01

Weighted average shares outstanding:
Basic 79,571,399 71,387,438
Diluted 79,571,399 96,346,846

Contact:

Neoprobe Corporation
Brent Larson, Vice President / CFO, 614-822-2330
OR
The Shoreham Group

Neoprobe Announces First Quarter Results

Business Update and Conference Call Scheduled

Press Release Source: Neoprobe Corporation On Wednesday April 28, 2010, 4:35 pm

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2010. First quarter 2010 revenues were $2.7 million, consistent with the record revenue reported for the first quarter of 2009. Gross profit for the first quarter of 2010 was $1.8 million, compared to $1.9 million for the first quarter of 2009. Operating expenses increased to $3.5 million for the first quarter of 2010 from $2.1 million for the first quarter of 2009. Neoprobe’s loss from operations for the first quarter of 2010 was $1.7 million compared to $203,000 for the first quarter of 2009.

For the first quarter of 2010, Neoprobe reported a net loss attributable to common stockholders of $2.5 million, or $0.03 per share, compared to net income attributable to common stockholders of $754,000, or $0.01 per share, for the first quarter of 2009. As discussed more fully below, the first quarter 2009 net income attributable to common stockholders was primarily due to mark-to-market adjustments related to derivative accounting treatment required for certain financial instruments on the Company’s balance sheet.

Brent Larson, Neoprobe’s Vice President, Finance and CFO, said, “Gamma detection device revenue for the first quarter of 2010 remained steady compared to the same period in 2009. Increased probe sales volumes offset declines in console sales and a minor decline in sales prices. Gross margins from our device sales declined slightly to 67% for the first quarter of 2010 compared to 69% for the same period in the prior year due to net changes in product mix and the impact of the decline in sales prices. Our gamma detection device line continues to show strong overall results and generate cash flow to cover our corporate overhead and contribute to our product development costs.”

David Bupp, Neoprobe’s President and CEO, said, “Our operating expenses increased for the first quarter of 2010 compared to last year as chemistry, manufacturing and control activities and other development expenses associated with preparing to submit a new drug application (NDA) for Lymphoseek® have accelerated. During the first quarter of 2010, we were pleased to announce the positive outcome of a meeting with FDA regarding a review of results from our Phase 3 clinical trial for Lymphoseek in subjects with breast cancer or melanoma. Related to the positive outcome of the regulatory meeting and the activities necessary to support the NDA, we have added headcount and geared up other activities to prepare for and to support the filing of the NDA. We believe the positive outcome of this FDA meeting and our other activities have positioned us well for the filing of the NDA later this summer. Our general and administrative costs for the first quarter also increased compared to the prior year primarily related to increased stock and compensation costs.”

During the first quarter of 2009, the Company was required to adopt certain authoritative guidance related to the accounting treatment for derivative liabilities. Under the applicable accounting rules for financial instruments, embedded features of the Company’s notes and preferred stock and the related warrants to purchase common stock were considered derivative liabilities because these instruments contained language that provided for the resetting of the instruments’ exercise/conversion prices in the event that the Company issues common stock at prices below the exercise/conversion prices of the respective instruments. Treatment of these instruments as derivative liabilities resulted in them being required to be reflected on the Company’s balance sheet at their fair values (i.e., marked to market) based on certain assumptions, including the trading price of the Company’s common stock. The adoption of these rules resulted in our recording $1.5 million in non-cash income for the first quarter of 2009 related to marking such derivative liabilities to market as required by the guidance. Excluding the $1.5 million mark-to-market adjustment, the Company would have generated a net loss attributable to common shareholders of $771,000 for the first quarter of 2009. Neoprobe’s management believes, however, that the inclusion of such mark-to-market adjustments in the Company’s financial results does not appropriately communicate the results of the Company’s operating performance and development activities to our investors. As a result, Neoprobe’s management believes the ability of investors to analyze Neoprobe’s business trends and to understand Neoprobe’s performance may be better served from reviewing certain operational measures such as revenues, development expenses and income (loss) from operations. During the third quarter of 2009, Neoprobe agreed with the holder of the instruments with derivative characteristics to eliminate the price reset features that had substantially caused the derivative treatment of the instruments, thereby permitting the Company to effectively extinguish the majority of its derivative liabilities. This action should minimize the subsequent impact on our financial results which might have otherwise resulted from fluctuations in the trading price of the Company’s common stock.

Neoprobe’s President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company’s results for the first quarter of 2010 during a conference call scheduled for 11:00 AM ET, Thursday, April 29, 2010. During the conference call, Messrs. Bupp and Larson will provide a business update and discuss the Company’s results for the first quarter of 2010. Neoprobe’s Vice President, Pharmaceutical Research and Clinical Development, Frederick Cope, Ph.D., will also be available to respond to questions regarding Lymphoseek’s development progress.

Conference Call Information
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
Date: April 29, 2010 Available until: May 6, 2010
Time: 11:00 AM ET Toll-free (U.S.) Dial in # : 877-660-6853
International Dial in # : 201-612-7415
Toll-free (U.S.) Dial in # : 877-407-8033 Replay pass codes (both
International Dial in # : 201-689-8033 required for playback):
Account # : 286
Conference ID # : 349832

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

NEOPROBE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2010 2009
(unaudited)
Assets:

Cash $ 5,956,271 $ 5,639,842
Other current assets 2,726,780 2,977,323
Non-current assets 581,503 400,594

Total assets $ 9,264,554 $ 9,017,759


Liabilities and stockholders' deficit:

Current liabilities, including current portion of notes payable $ 3,422,520 $ 2,402,647
Notes payable, long term (net of discounts) 10,951,924 10,945,907
Derivative liabilities 2,380,956 1,951,664
Other liabilities 549,300 587,393
Preferred stock 3,000,000 3,000,000
Stockholders' deficit (11,040,146 ) (9,869,852 )

Total liabilities and stockholders' deficit

$

9,264,554

$

9,017,759



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
March 31, March 31,
2010 2009
(unaudited) (unaudited)

Total revenues $ 2,682,872 $ 2,682,221
Cost of goods sold 888,867 826,363
Gross profit 1,794,005 1,855,858

Operating expenses:
Research and development 2,401,672 1,221,969
Selling, general and administrative 1,128,202 837,323
Total operating expenses 3,529,874 2,059,292

Loss from operations (1,735,869 ) (203,434 )

Interest expense (284,438 ) (457,134 )
Change in derivative liabilities (429,292 ) 1,525,365
Other income, net 1,358 9,673

(Loss) income from continuing operations (2,448,241 ) 874,470

Discontinued operations (11,873 ) (60,349 )

Net (loss) income (2,460,114 ) 814,121

Preferred stock dividends (60,000 ) (60,000 )

Loss (income) attributable to common stockholders $ (2,520,114 ) $ 754,121

Loss (income) per common share (basic and diluted):
Continuing operations $ (0.03 ) $ 0.01
Discontinued operations $ (0.00 ) $ -
Loss (income) attributable to common stockholders $ (0.03 ) $ 0.01

Weighted average shares outstanding:
Basic 79,571,399 71,387,438
Diluted 79,571,399 96,346,846

Contact:

Neoprobe Corporation
Brent Larson, Vice President / CFO, 614-822-2330
OR
The Shoreham Group

No, you are just living on the edge! so am I.

BIOMED Alert on POSC...POSC will be releasing some details about the partnership with the NYSE co in the morning. Details will be on the subscriber section of the the page in 30 min. or so

BIOMED Alert on POSC...POSC will be releasing some details about the partnership with the NYSE co in the morning. Details will be on the subscriber section of the the page in 30 min. or so

BIOMED Alert on POSC...POSC will be releasing some details about the partnership with the NYSE co in the morning. Details will be on the subscriber section of the the page in 30 min. or so.

That was my understanding also.

Cytori to Webcast First Quarter Financial Results

businesswire

Press Release Source: Cytori Therapeutics On Wednesday April 28, 2010, 7:00 am EDT

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX - News) will host a webcast to discuss their first quarter financial results on Thursday, May 6, 2010 at 10:30 AM Eastern Time. Prior to the webcast at approximately 7:00 AM Eastern Time on May 6, Cytori will post a shareholder letter to its Investor Relations homepage, which will review Cytori's first quarter performance, provide an update on commercialization activities and discuss recent developments.

The webcast will be available both live and by replay two hours after the call on the Company's website, under "Webcasts" on the Investor Relations page (http://ir.cytoritx.com).

About Cytori

Cytori is an emerging leader in regenerative medicine, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. www.cytori.com

Contact:

Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytori.com

Good Morning..Rise and Shine,lets make some money today!